Diabetes & metabolic syndrome · 2026
The prevalence of cardiometabolic and renal long-term conditions in individuals with type 2 diabetes mellitus: a global umbrella review.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hassen Sarah, Razieh Cameron, O'Mahoney Lauren, Wilkinson Thomas J, Gawlik-Lipinski Aleksandra, Salisu-Olatunji Shukrat O, Hickman Elizabeth, Kundu Monica, Khunti Kamlesh, Gillies Clare L
Аннотация
BACKGROUND AND AIMS: There is a high prevalence of long-term conditions (LTCs) among people with type 2 diabetes (T2D). This umbrella review synthesises and collates the existing evidence.
METHODS: This review was registered in PROSPERO (CRD42024490470) and follows the Joanna Briggs Institute guidelines (JBI) for umbrella reviews. Comprehensive searches of Ovid Medline, Ovid Embase, Cochrane, and CINAHL databases were conducted. Systematic reviews of observational studies on cardiometabolic and renal LTCs in T2D were included. Quality was assessed using the JBI Critical Appraisal Checklist for systematic reviews, and study results were narratively synthesised.
RESULTS: Out of 10,721 records, 20 systematic reviews (15 with meta-analyses) were included, comprising 675 primary studies. The most commonly reported cardiometabolic condition in T2D was cardiovascular disease, with a pooled prevalence ranging from 13·0% (95% CI: 11·0,15·0) to 46·0% (39·0, 54·0), followed by heart failure with the highest pooled prevalence reported as 25·0% (21·0, 28·0). For renal conditions in T2D, the overall pooled prevalence for nephropathy ranged from 4·2% (3·2, 5·3) to 38·0% (14·0, 63·0), while chronic kidney disease reported prevalence ranged from 18·2% (15·1, 21·4) to 35·5% (25·9, 45·5). The prevalence of these conditions varied by sex and income status, with higher rates observed in males and low-income and middle-income countries.
CONCLUSION: This review highlights the significant prevalence of cardiometabolic and renal LTCs in T2D, highlighting the need for targeted and holistic management approaches to address these comorbidities effectively.
METHODS: This review was registered in PROSPERO (CRD42024490470) and follows the Joanna Briggs Institute guidelines (JBI) for umbrella reviews. Comprehensive searches of Ovid Medline, Ovid Embase, Cochrane, and CINAHL databases were conducted. Systematic reviews of observational studies on cardiometabolic and renal LTCs in T2D were included. Quality was assessed using the JBI Critical Appraisal Checklist for systematic reviews, and study results were narratively synthesised.
RESULTS: Out of 10,721 records, 20 systematic reviews (15 with meta-analyses) were included, comprising 675 primary studies. The most commonly reported cardiometabolic condition in T2D was cardiovascular disease, with a pooled prevalence ranging from 13·0% (95% CI: 11·0,15·0) to 46·0% (39·0, 54·0), followed by heart failure with the highest pooled prevalence reported as 25·0% (21·0, 28·0). For renal conditions in T2D, the overall pooled prevalence for nephropathy ranged from 4·2% (3·2, 5·3) to 38·0% (14·0, 63·0), while chronic kidney disease reported prevalence ranged from 18·2% (15·1, 21·4) to 35·5% (25·9, 45·5). The prevalence of these conditions varied by sex and income status, with higher rates observed in males and low-income and middle-income countries.
CONCLUSION: This review highlights the significant prevalence of cardiometabolic and renal LTCs in T2D, highlighting the need for targeted and holistic management approaches to address these comorbidities effectively.